Insulet Corporation $PODD Shares Sold by Advisors Capital Management LLC

Advisors Capital Management LLC lessened its stake in shares of Insulet Corporation (NASDAQ:PODD) by 7.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,656 shares of the medical instruments supplier’s stock after selling 207 shares during the period. Advisors Capital Management LLC’s holdings in Insulet were worth $835,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Zions Bancorporation National Association UT acquired a new position in Insulet during the first quarter worth approximately $26,000. Larson Financial Group LLC boosted its holdings in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 81 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 69 shares during the last quarter. SouthState Corp increased its holdings in Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 76 shares in the last quarter. Finally, Kozak & Associates Inc. acquired a new stake in Insulet during the 2nd quarter valued at $32,000.

Insider Activity at Insulet

In related news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.39% of the company’s stock.

Analyst Ratings Changes

PODD has been the subject of several analyst reports. Truist Financial boosted their price target on Insulet from $365.00 to $390.00 and gave the company a “buy” rating in a report on Friday, November 7th. Stifel Nicolaus assumed coverage on shares of Insulet in a research note on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price target for the company. Barclays raised their price objective on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. UBS Group boosted their price objective on Insulet from $320.00 to $355.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Finally, Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $374.10.

Insulet Price Performance

Shares of PODD opened at $332.70 on Friday. The business’s 50-day moving average is $323.58 and its 200-day moving average is $312.46. The company has a market capitalization of $23.40 billion, a price-to-earnings ratio of 101.12, a P/E/G ratio of 2.64 and a beta of 1.39. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.11. The company had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s revenue was up 29.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.